Co-Diagnostics, Inc. Announces Participation in Research Project with Stanford University
June 01 2018 - 06:30AM
Business Wire
CoPrimers™ used in proof of concept
evaluation
Co-Diagnostics, Inc. (NASDAQ: CODX), a diagnostics company
with a unique, proprietary platform for the development of
molecular diagnostics, announced today that the Company’s CoPrimer™
technology is being employed to achieve the objectives of a
research project conducted by the Wang Group at Stanford
University.
The purpose of the study is to develop more efficient methods to
detect multiple genetic mutations in the EGFR (epidermal growth
factor receptor) gene, including the most frequently occurring
mutations in lung cancer, within a single reaction. The
investigators have been conducting research into the subject using
commercially available primers for several years, the results of
which have previously been published, and contacted Co-Diagnostics
to utilize the Company’s technology to further improve
comprehensive detection methods of mutations that are known to
cause cancer. It is anticipated that the results of the current
study will be compiled and published later in 2018.
Co-Diagnostics CEO Dwight Egan remarked: “We were honored that
the Wang Group at Stanford University approached Co-Diagnostics and
expressed interest in applying our CoPrimer technology to their
endeavors to improve detection of cancer. The ability to multiplex
within a single reaction, along with the heightened specificity and
allowing for a massive reduction in false positives, are some of
the most valuable benefits of this technology, making it ideal for
cancer detection and liquid biopsy applications. The continued
results of this study will help to further advance the capabilities
of our technology and lay the groundwork for products to service
these fast-growing markets.”
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular
diagnostics company that has developed and intends to manufacture
and sell reagents used for diagnostic tests that function via the
detection and/or analysis of nucleic acid molecules (DNA or RNA),
and to sell diagnostic equipment from other manufacturers as
self-contained lab systems.
Forward-Looking Statements:
This press release contains forward-looking statements.
Forward-looking statements can be identified by words such as
"believes," "expects," "estimates," "intends," "may," "plans,"
"will" and similar expressions, or the negative of these words.
Such forward-looking statements are based on facts and conditions
as they exist at the time such statements are made and predictions
as to future facts and conditions. Readers of this press
release are cautioned not to place undue reliance on any
forward-looking statements. The Company does not undertake
any obligation to update any forward-looking statement relating to
matters discussed in this press release, except as may be required
by applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180601005234/en/
Company Contact:Co-Diagnostics, Inc.Andrew
BensonCo-Diagnostics Investor
Relations801-438-1036investors@codiagnostics.comorInvestor
Contact:Lytham Partners, LLCJoe Diaz, Robert Blum and Joe
Dorame602-889-9700codx@lythampartners.com
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From Mar 2023 to Mar 2024